3rd Annual Hematologic Malignancies Symposium

 

3rd Annual Hematologic Malignancies Symposium
A

2021 Updates on FLT3m Frontline AML: Does HiDAC+Chemo Provide OS Benefit? What Is the Role of MRD? Is Sorafenib a Good Maintenance Choice?

By 3rd Annual Hematologic Malignancies Symposium FEATURING Alexander Perl
By 3rd Annual Hematologic Malignancies Symposium FEATURING Alexander Perl
144 views
April 8, 2021
Comments 0
Login to view comments. Click here to Login
Videos
26:33

2021 Updates on FLT3m Frontline AML: Does HiDAC+Chemo Provide OS Ben…

3rd Annual Hematologic Malignancies Symposium

A. Perl

144 views
07:34

2021 Updates on FLT3m R/R AML: What Is the Current Standard of Care?…

3rd Annual Hematologic Malignancies Symposium

A. Perl

216 views
15:35

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve O…

3rd Annual Hematologic Malignancies Symposium

G. Roboz

126 views
22:10

MD Anderson Update on the Role of IDH Inhibition in AML: Targeted Th…

3rd Annual Hematologic Malignancies Symposium

C. DiNardo

231 views
26:23

HMA Resistance & Treatment After HMT Failure in MDS: Aza vs. CCR, In…

3rd Annual Hematologic Malignancies Symposium

H. Carraway

128 views
15:41

IDH Inhibitors in MDS: Frequency & Prognosis, Mutations, Therapy Out…

3rd Annual Hematologic Malignancies Symposium

A. Wei

418 views